Methodology published · Market data, model notes, and corrections process are public · Data policy · Corrections policy

NYSE · HEALTHCARE · Financials

AbbVie Inc financial statements.

Q1 FY2026 snapshot — revenue, profitability, balance-sheet strength, and cash generation. Provider-attributed so you can verify any line.

Balance sheet coverage

ABBV assets, liabilities, debt, and equity are now visible.

The financials page now surfaces the balance sheet alongside income and cash-flow statements, with full quarterly and annual statement rows available in the explorer below.

20 quarterly · 17 annual rows · Market data feed · balance-sheet-statement quarterly

Open balance sheet table

Latest period

Q1 FY2026

20 quarterly · 17 annual rows

Assets / liabilities

$136.46B

Liabilities $143.07B

Cash / debt

$9.39B

Net cash -$63.47B

Equity / working capital

-$6.61B

Working capital -$8.57B

Financial statement period

ABBV statement history

ProfitabilityIncome statementRevenue, expenses, margins, and income quality20 quarterly rows Capital structureBalance sheetAssets, liabilities, debt, equity, and share count20 quarterly rows Cash generationCash flowOperating cash flow, CapEx, FCF, buybacks, and dividends20 quarterly rows

Income statement

Quarterly and annual rows for revenue, operating leverage, earnings quality, and margin direction.

8 / 20 Quarterly

Period	Revenue	Gross profit	Operating income	Interest income	Continuing ops	Net income	Comprehensive income	Net margin	Revenue QoQ	Net income QoQ
Q1 FY2026	$15.00B	$10.78B	$4.73B	$72.00M	$697.00M	$699.00M	—	4.66%	-9.7%	-61.5%
Q4 FY2025	$16.62B	$12.07B	$5.81B	$59.00M	$1.81B	$1.82B	—	10.93%	+5.3%	+876.3%
Q3 FY2025	$15.78B	$10.47B	$1.90B	$72.00M	$188.00M	$186.00M	—	1.18%	+2.3%	-80.2%
Q2 FY2025	$15.42B	$11.08B	$4.89B	$62.00M	$941.00M	$938.00M	—	6.08%	+15.6%	-27.1%
Q1 FY2025	$13.34B	$9.34B	$3.73B	$73.00M	$1.29B	$1.29B	—	9.64%	-11.6%	+5945.5%
Q4 FY2024	$15.10B	$10.71B	-$1.49B	$92.00M	-$23.00M	-$22.00M	—	-0.15%	+4.4%	-101.4%
Q3 FY2024	$14.46B	$10.25B	$3.83B	$129.00M	$1.56B	$1.56B	—	10.80%	-0.0%	+13.9%
Q2 FY2024	$14.46B	$10.26B	$4.00B	$220.00M	$1.37B	$1.37B	—	9.47%	+17.5%	+0.1%

Balance sheet

Provider-attributed balance-sheet rows for assets, liabilities, liquidity, debt, equity, and shares outstanding.

8 / 20 Quarterly

Period	Cash	Current assets	Current liabilities	Total assets	Total liabilities	Total debt	Capital leases	Total equity	Shares	Debt QoQ
Q1 FY2026	$9.39B	$33.53B	$42.10B	$136.46B	$143.07B	$72.86B	—	-$6.61B	1.77B	+5.8%
Q4 FY2025	$5.23B	$29.06B	$43.29B	$133.96B	$137.19B	$68.87B	—	-$3.23B	1.77B	+0.2%
Q3 FY2025	$5.63B	$28.54B	$39.39B	$133.90B	$136.50B	$68.74B	—	-$2.60B	1.77B	-2.5%
Q2 FY2025	$6.47B	$29.26B	$39.77B	$137.18B	$137.32B	$70.48B	—	-$138.00M	1.77B	+0.8%
Q1 FY2025	$5.17B	$27.68B	$36.40B	$136.16B	$134.70B	$69.89B	—	$1.46B	1.77B	+3.0%
Q4 FY2024	$5.52B	$25.58B	$38.75B	$135.16B	$131.80B	$67.84B	—	$3.36B	1.77B	-4.6%
Q3 FY2024	$7.26B	$27.79B	$43.06B	$143.42B	$137.35B	$71.08B	—	$6.07B	1.77B	+0.6%
Q2 FY2024	$13.13B	$33.82B	$41.91B	$141.94B	$135.12B	$70.63B	—	$6.82B	1.77B	-4.5%

Cash flow

Operating cash generation, capital expenditure, free cash flow, buybacks, dividends, and cash movement.

8 / 20 Quarterly

Period	Operating cash flow	CapEx	Free cash flow	Net income	Stock comp	Debt issuance	Dividends paid	Buybacks	Change in cash	FCF QoQ
Q1 FY2026	$3.83B	$265.00M	$3.56B	$697.00M	$444.00M	—	$3.09B	-$1.49B	—	-27.1%
Q4 FY2025	$5.22B	$329.00M	$4.89B	$1.82B	$157.00M	—	$2.91B	-$3.00M	—	-25.0%
Q3 FY2025	$7.02B	$504.00M	$6.52B	$188.00M	$209.00M	—	$2.91B	$4.00M	—	+33.5%
Q2 FY2025	$5.15B	$269.00M	$4.88B	$941.00M	$179.00M	—	$2.91B	-$12.00M	—	+248.9%
Q1 FY2025	$1.64B	$235.00M	$1.40B	$1.29B	$410.00M	—	$2.92B	-$961.00M	—	-79.3%
Q4 FY2024	$7.05B	$291.00M	$6.76B	$4.29B	$674.00M	—	$2.75B	-$358.00M	—	+30.0%
Q3 FY2024	$5.45B	$249.00M	$5.20B	$1.59B	$181.00M	—	$2.75B	-$17.00M	—	+156.1%
Q2 FY2024	$2.27B	$241.00M	$2.03B	$1.37B	$218.00M	—	$2.75B	-$9.00M	—	-47.2%

Valuation and returns

Enterprise value: $447.90B; Market data feed · key-metrics-ttm.enterpriseValueTTM

Return on equity: 62.30%; Market data feed · ratios-ttm.returnOnEquityTTM

Return on assets: 10.00%; Market data feed · ratios-ttm.returnOnAssetsTTM

Debt / equity: Pending; Current ratio 0.80

These metrics are core inputs to TECHi’s Forward model and quant scoring — the same signals that drive our multi-horizon edge over generic analyst views.

Annual revenue and income multiples

Annual revenue: $61.16B; Latest annual statement · FY FY2025 · Market data feed · income-statement annual

Annual net income: $4.23B; Latest annual statement · FY FY2025 · Market data feed · income-statement annual

Market cap / revenue: 6.29; Market value divided by annual revenue

Market cap / income: 91.02; Market value divided by annual net income

These multiples are key inputs to TECHi’s Forward model and quant framework — the same signals that power our multi-horizon edge.

Annual sales and income multiple

Market cap / annual revenue6.29

Market cap / annual income91.02

EV / annual revenue7.32

EV / annual income22.29

Interest burden

Interest paid / expense$2.89B

Interest / revenue4.73%

Interest / market cap0.75%

Interest / income68.46%

Uses absolute annual net income when positive or negative

Latest income statement · Q1 FY2026

Revenue: $15.00B; +12.4% YoY

Gross profit: $10.78B; 71.88%

Operating income: $4.73B; 31.56%

Net income: $699.00M; 4.66%

Revenue, net income, and free cash flow

Revenue$15.00BNet income$699.00MFree cash flow$3.56B

Q4 FY2024Q3 FY2025Q1 FY2026

Quarterly statement rows, shown on one common dollar scale so margin compression and cash conversion stand out quickly.

Efficiency

Revenue / employee: Pending; Employee count pending

Net income / employee: Pending; TTM net income divided by employees

FCF / employee: Pending; TTM free cash flow divided by employees

Market cap / employee: Pending; Live value per employee

Growth vs cost pressure

Revenue growth YoY+12.4%

Debt growth YoY+4.2%

Operating expense growth YoY+7.9%

Cash conversion

FCF margin31.61%

CapEx / revenue2.18%

FCF / net income5.46

Above 1.0 means cash flow exceeds reported earnings

EBITDA margin26.94%

OCF / revenue33.79%

Quarterly margin heatmap

Gross margin

Q1 FY2026

71.88%

Q4 FY2025

72.61%

Q3 FY2025

66.38%

Q2 FY2025

71.82%

Q1 FY2025

70.01%

Q4 FY2024

70.89%

Operating margin

Q1 FY2026

31.56%

Q4 FY2025

34.96%

Q3 FY2025

12.07%

Q2 FY2025

31.73%

Q1 FY2025

27.98%

Q4 FY2024

-9.87%

Net margin

Q1 FY2026

4.66%

Q4 FY2025

10.93%

Q3 FY2025

1.18%

Q2 FY2025

6.08%

Q1 FY2025

9.64%

Q4 FY2024

-0.15%

Latest quarter expense mix

Cost of revenue$4.22B

Operating expenses$6.05B

R&D$2.47B

SG&A$3.58B

Profit bridge

EBIT$1.76B

EBITDA$3.69B

Pretax income$1.04B

Interest expense$717.00M

Tax expense$342.00M

Detailed income lines

Interest income$72.00M

Net interest income-$645.00M

Investment income net—

Continuing operations income$697.00M

Comprehensive income—

Other income statement lines

Other non-operating income—

Income before tax$1.04B

Income tax expense$342.00M

Balance sheet · Q1 FY2026

Cash & equivalents: $9.39B

Total debt: $72.86B

Net cash: -$63.47B; Net debt position

Total equity: -$6.61B

Balance sheet detail

Current assets: $33.53B

Current liabilities: $42.10B

Inventory: $5.05B

Receivables: $12.48B

Property, plant & equipment: Pending

Current debt: $8.33B

Long-term debt: $64.53B

Shares outstanding: 1.77B

Balance sheet assets detail

Short-term investments—

Long-term investments$268.00M

Goodwill$35.57B

Intangible assets$50.87B

Balance sheet liabilities detail

Deferred revenue—

Current long-term debt$8.33B

Capital lease obligations—

Treasury stock—

Debt and liquidity

Debt / revenue1.16

Debt / income20.02

Debt / EBITDA4.31

Interest coverage6.60

Operating income / interest expense

Cash / debt0.13

Quick ratio0.68

Current assets less inventory / current liabilities

Shares outstanding trend

Shares1.77B

Q4 FY2024Q3 FY2025Q1 FY2026

Quarterly balance-sheet shares outstanding, useful for spotting buybacks, dilution, and split-adjusted share-count drift.

Cash generation

Operating cash flow: $3.83B

Capital expenditure: $265.00M

Free cash flow: $3.56B

Capital returned: $1.60B; Buybacks + dividends paid

Cash-flow detail

Depreciation & amortization: $1.94B

Investing cash flow: -$574.00M

Financing cash flow: $919.00M

Change in receivables: Pending

Change in inventory: -$184.00M

Stock issuance: Pending; Provider field pending

Buybacks: -$1.49B

Net buybacks: -$1.49B; Repurchases less stock issuance

Dividends paid: $3.09B

Cash flow read

ABBV converts most of its earnings into cash.

Free cash flow of $3.56B versus $699.00M of reported net income means accruals aren't doing much heavy lifting — the cash is showing up alongside the earnings. That's the cleanest profile a fundamentals desk wants to see.

Frequently asked

Common questions.

Where can I see ABBV financial statements?

The ABBV Financials page hosts the latest income statement, balance sheet, and cash-flow statement for AbbVie Inc — quarterly and annual views, with TECHi's source attribution next to every line.

What is AbbVie Inc's revenue trend?

Quarterly and annual revenue, gross profit, operating income, and net income trends for AbbVie Inc are charted at the top of the ABBV Financials page; analyst estimates for the next two periods overlay the historical bars.

What is AbbVie Inc's profit margin?

AbbVie Inc reports a net margin of 5.79%. Gross / operating / net margin trends and the segment mix that drives them are broken out on the ABBV Financials page.

Does AbbVie Inc have positive free cash flow?

Operating cash flow, capital expenditure, and free cash flow are tracked quarterly on the ABBV Financials page. FCF margin and FCF yield are normalized on the /quote/ABBV/statistics/ page.